Fig 11.

Impact of drug combinations on Candida albicans filamentation. (A) Cell morphologies of strains SC5314, SP-945, and P60002 treated with either DMSO, fluconazole (FLC) (10 µg/mL), 1,4-benzodiazepines (1,4-BZDs) (PA158 or PA162, 100 µM), or a combination of FLC (10 µg/mL) and 1,4-BZDs (100 µM). Cells were incubated in YPD at 37°C for 2 hours prior to imaging. Images show representative cells for the respective conditions, at 40X magnification. Scale bar, 10 µm. (B) The fraction of each morphology was quantified for at least 200 cells per condition from four biological replicates. Asterisks indicate significant differences relative to DMSO, t-test, *P < 0.05. Error bars represent ± SEM. (C) Impact of 1,4-BZDs (100 µM) on FLC susceptibility (MIC₅₀) and tolerance (SMG) for mutants affecting cell morphology (see schematic on the right side) and corresponding parental strain. Changes in MIC₅₀ and SMG are shown relative to levels observed with DMSO treatment. Heatmaps show average values from three to six biological replicates.